GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of someone explain receptor to me like I have not read a paper in years — 49 comments in the full submission. View in context.
4k
c/glp1science·submitted 1 year ago by u/split_dose_sceptic

someone explain receptor to me like I have not read a paper in years

Questionbranch of 6 comments

someone explain receptor to me like I have not read a paper in years. If this has been answered properly somewhere, link me and I will delete. GIP receptor biology is genuinely unsettled — there is a live argument about agonism versus antagonism at the receptor — and the clinical results are robust regardless, which…

Read the full submission and all 49 comments →

This branch

6 comments, started 1 year ago
u/priya_guerrero401 points·1 year ago

Not convinced by the linearity assumption. Dose-response in this class is not linear and the trials show it.

replysharereportpermalink
u/ismael_eriksen-36 points·1 year ago

Disagree. That is a preclinical finding in a rodent model and you are stating it as human pharmacology.

replysharereportpermalink
u/incretin_ivyMOD210 points·1 year ago

Speculation is welcome here if it is labelled. This one has been relabelled rather than removed.

replysharereportpermalink
u/aleksi_lehtinen105 points·1 year ago

Yes. The central component is the one that explains the reports on this site better than gastric emptying does.

replysharereportpermalink
u/gradient_goblin163 points·1 year ago

Speculation is welcome here if it is labelled.

incretin_ivy is right that mechanism gives direction and not magnitude. Worth pinning.

replysharereportpermalink
[deleted]186 points·1 year ago

[deleted]

replysharereportpermalink

← back to the whole thread

About c/glp1science

The mechanism layer: incretin physiology, receptor distribution, gastric emptying, central appetite signalling, glucagon-receptor contribution, amylin co-agonism, and the pharmacokinetics that make weekly dosing possible. Papers get cited by journal and year or they get a [needs source] reply.

50kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/glp1science
c/glp1science rules
  1. Cite the paper: journal, year, first author. Links optional, citation mandatory.
  2. Mechanistic speculation is welcome if flaired as speculation.
  3. No extrapolating rodent data to human dosing without saying that is what you are doing.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/trialwatch_theou/gastric_emptying_gu/sig_figs_sam
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →